Electrophysiological Evaluation of Syncope

Published on 21/06/2015 by admin

Filed under Cardiovascular

Last modified 21/06/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2767 times

Chapter 29 Electrophysiological Evaluation of Syncope

Electrophysiology Testing

Indications

EP testing can provide important diagnostic information in patients presenting with syncope. The results of EP testing can be useful in establishing a diagnosis of sick sinus syndrome, carotid sinus hypersensitivity, heart block, supraventricular tachycardia (SVT), and ventricular tachycardia (VT). The indications for EP testing in the evaluation of patients with syncope are outlined in detail in the European Society of Cardiology (ESC) Guidelines on Management of Syncope (Table 29-1).1 It is generally accepted that EP testing should be performed in patients when the initial evaluation suggests an arrhythmic cause of syncope (class 1). This group of patients includes those with an abnormal electrocardiogram (ECG), structural heart disease, or both. Patients whose clinical history suggests an arrhythmic cause of syncope and those with a family history of sudden death are also included in this group. It is also generally accepted that EP testing should not be performed in patients with a normal ECG and no heart disease and in whom the clinical history does not suggest an arrhythmic cause of syncope (class 3). Class 2 indications for performing an EP study are shown in Table 31-1. These indications suggest that EP testing is appropriate when the results may affect treatment and in patients with “high-risk” occupations, in which case every effort should be expended to determine the probable cause of syncope.

Table 29-1 Indications for Electrophysiology Testing in the Evaluation of Patients with Syncope

CLASS 1
When the initial evaluation of syncope suggests an arrhythmic cause of syncope
In patients with abnormal electrocardiography, structural heart disease, or both
In patients with syncope associated with palpitations or a family history of sudden death
CLASS 2
To evaluate the exact nature or mechanism of an arrhythmia that has been identified as the cause of syncope
In patients with cardiac disorders in which arrhythmia induction has a bearing on the selection of therapy
In patients with syncope who are in a high-risk occupation and in whom every effort to exclude a cardiac cause of syncope is warranted
CLASS 3
In patients with normal electrocardiograms and no heart disease and no palpitations

Electrophysiology Testing Protocol

When EP testing is undertaken in a patient with syncope, a comprehensive EP evaluation should be performed. This should include an evaluation of sinus node function by measuring the sinus node recovery time (SNRT) and an evaluation of atrioventricular (AV) conduction by measurement of the H-V interval (His bundle to ventricle conduction time) at baseline, with atrial pacing, and following pharmacologic challenge with intravenous procainamide. In addition, programmed electrical stimulation using standard techniques should be performed to evaluate the inducibility of ventricular and supraventricular arrhythmias. The minimal suggested EP protocol recommended by the ESC is provided in Table 29-2. Although the minimal suggested EP protocol recommended by the ESC includes only double extrastimuli and two basic drive train cycle lengths, it is common practice in the United States to include triple extrastimuli and three basic drive train cycle lengths. It is also common practice to limit the shortest coupling interval to 200 ms. In select patients, when a ventricular arrhythmia is highly suspected, EP testing with atrial and ventricular programmed stimulation may be repeated after an infusion of isoproterenol. In my experience, this is of particular importance in the presence of suspicion of a supraventricular arrhythmia such as AV nodal re-entrant tachycardia or orthodromic AV reciprocating tachycardia as the cause of syncope.

Table 29-2 Minimal Suggested Protocol for Electrophysiology Testing for the Diagnosis of Syncope

Measurement of sinus node recovery time and corrected sinus node recovery time by repeated 30- to 60-second sequences of atrial pacing at 10 to 20 beats/min higher than the sinus rate and at two faster pacing rates.
Measurement of the H-V interval (His bundle to ventricle) during sinus rhythm and with incremental atrial pacing. If the baseline study is inconclusive, pharmacologic provocation with an infusion of procainamide (10 mg/kg IV) is recommended.
To evaluate the exact nature or mechanism of an arrhythmia that has been identified as the cause of syncope.
Programmed electrical stimulation in the ventricle to assess ventricular inducibility.
Programmed stimulation should be performed at the apex and outflow tract and at two basic drive cycle lengths with up to two extrastimuli.
Programmed electrical stimulation to evaluate the substrate for inducibility of supraventricular arrhythmias.

Assessment of Sinus Node Function

Sinus node function is evaluated during EP testing primarily by determining the SNRT, which is determined by pacing the right atrium at cycle lengths between 600 and 350 ms for 30 to 60 seconds. The SNRT is defined as the interval between the last paced atrial depolarization and the first spontaneous atrial depolarization resulting from activation of the sinus node. The SNRT is corrected for the underlying sinus cycle length (SCL) and expressed as the corrected SNRT (CSNRT = SNRT – SCL). An SNRT longer than 1.6 seconds or a corrected SNRT greater than 525 ms is generally considered abnormal. A secondary pause is defined as an inappropriately long pause between the beats that follow the first sinus recovery beat after atrial overdrive pacing. Evaluation of secondary pauses increases the sensitivity of the SNRT in the detection of sinus node dysfunction. Identification of sinus node dysfunction as the cause of syncope is uncommon during EP tests (<5%). The sensitivity of an abnormal SNRT or CSNRT is approximately 50% to 80%. The specificity of an abnormal SNRT or CSNRT is greater than 95%.2 The prognostic value of an abnormal CSNRT or SNRT has not been well defined. Gann and colleagues demonstrated a relationship between an abnormal SNRT and the effect of pacemaker placement on symptoms.3 Another study reported that patients with a markedly prolonged CSNRT (>800 ms) had a risk of syncope eight times higher than that with CSNRTs less than 800 ms.4 It is important to note that the absence of evidence of sinus node dysfunction during EP testing does not exclude a bradyarrhythmia as the cause of syncope.5

Assessment of Atrioventricular Conduction

During EP testing, AV conduction is assessed by measuring the A-H interval (AV node to His bundle conduction time) and the H-V interval by determining the response of AV conduction to incremental atrial pacing and atrial premature stimuli. If the results of an initial assessment of AV conduction in the baseline state are inconclusive, procainamide (10 mg/kg) may be administered intravenously and atrial pacing and programmed stimulation repeated. According to the 2004 ESC Guidelines on Management of Syncope, the findings at EP study that establish heart block as the probable cause of syncope are bi-fasicular block and a baseline HV interval longer than 100 ms or demonstration of second- or third-degree His-Purkinje block during incremental atrial pacing or when provoked by an infusion of procainamide (Table 29-3).1 According to these guidelines, the finding of an H-V interval between 70 and 100 ms is of less certain diagnostic value. Among studies that have reported the results of EP testing in evaluating patients with syncope, AV block was identified as the probable cause of syncope in approximately 10% to 15% of patients. Donateo and colleagues reported the results of a systematic evaluation of patients with syncope in the setting of a bundle branch block on their baseline ECG.6 Of 347 patients referred for evaluation of syncope, 55 had a baseline bundle branch block pattern. Systematic evaluation of these patients, including EP testing, resulted in a diagnosis of cardiac syncope in 25 patients (45%): AV block in 20 (36%), sick sinus syndrome in 2 (3.6%), VT in 1 (1.8%), and aortic stenosis in 2 (3.6%). Neurally mediated syncope was diagnosed in 22 patients (40%) and syncope remained unexplained in 8 (15%).

Table 29-3 Diagnostic Findings of Electrophysiology Testing for Syncope

Class 1 A normal EP study cannot completely exclude a tachyarrhythmia or a bradyarrhythmia as the cause of syncope.
When an arrhythmia is believed to be the likely cause of syncope, further evaluation, perhaps with a loop recorder, is recommended.
An abnormal finding on EP testing may not be diagnostic of the cause of syncope.
An EP study is considered to be diagnostic of the cause of syncope in the following situations:
Sinus bradycardia and a markedly prolonged CSNRT
Bi-fasicular block and a baseline H-V interval (His bundle to ventricle) of >100 ms or second- or third-degree His-Purkinje block with incremental atrial pacing
High-degree His-Purkinje block provoked with IV procainamide
Induction of sustained monomorphic VT
Induction of rapid SVT that reproduces the patient’s symptoms or results in hypotension
Class 2 The diagnostic value of an EP study is less well established:
When the H-V interval is >70 ms but <100 ms
With induction of PMVT or VF in patients with Brugada syndrome, ARVD, and those resuscitated from cardiac arrest
Class 3 The induction of PMVT or VF has a low predictive value in patients with an ischemic or dilated cardiomyopathy.

EP, Electrophysiology; CSNRT, corrected sinus node recovery time; IV

Buy Membership for Cardiovascular Category to continue reading. Learn more here